Head-to-head · free

Johnson & Johnson vs Lumexa Imaging

JNJ vs LMRI — return on capital, cash generation, margins and balance sheet side by side.

JNJ

4 / 4

measures where JNJ leads

LMRI

0 / 4

measures where LMRI leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureJNJ · FY2025LMRI
Revenue$94.2B—
Net income$26.8B—
Revenue growth (yearly, multi-year)3.3%—
Free cash flow$19.7B—
Free cash flow margin20.9%—
Net cash / (debt)——
ROIC21.1%—
Return on equity35.0%-12.6%
Gross margin67.9%15.4%
Operating margin27.2%2.6%
Net debt / EBITDA0.73x5.06x

Figures are as reported by each company; latest fiscal year shown.

Where Johnson & Johnson's cash went (FY2025)

Capital spending
$4.8B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full JNJ profile →

Where Lumexa Imaging's cash went

Not reported yet.

Full LMRI profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons